论文部分内容阅读
人们对抗心律失常药物对房颤病人除颤阈的影响了解甚微。早期研究表明:慢性房颤病人应用奎尼丁后进行直流同步电转复时,该药有减少除颤次数及能量的作用,一般在直流同步电复律前24小时内服用负荷量奎尼丁1200mg,但与其相反,Sodermark等对慢性房颤或房扑病人在直流电复律前以奎尼丁600～800mg每日两次,用2.5天与不用药者作比较,并未发现其对房颤除颤阈有何差别。氟卡胺,一种Ic类抗心律失常药,正越来越多地用于室上性心动过速的治疗,与奎尼丁比较,氟卡胺对房颤或房扑转为窦性心律的化学转复效果不如奎尼丁好,另一个不同点可能是对病人直流电复律成功所需的能量两者间存在着差异。由于缺乏氟卡胺对房颤病人除颤阈影响的数据,我们比较了房颤或房扑病人静注氟卡胺与否后所需直流电同
The effect of antiarrhythmic drugs on the defibrillation threshold in patients with atrial fibrillation is poorly understood. Early studies have shown that: after the application of quinidine in patients with chronic atrial fibrillation after DC synchronous electrical recovery, the drug has the effect of reducing the frequency and energy of defibrillation, the general DC synchronous cardioversion within 24 hours before taking the load of quinidine 1200mg , But in contrast, Sodermark and other patients with chronic atrial fibrillation or atrial flutter before DC cardioversion with quinidine 600 ~ 800mg twice daily with 2.5 days compared with no medication, and found no atrial fibrillation except What is the difference between Thresholds. Flecainide, an anti-arrhythmic agent of type Ic, is increasingly being used for the treatment of supraventricular tachycardia. Compared with quinidine, flecainide is converted to sinus rhythm in atrial fibrillation or atrial flutter The chemical conversion is not as good as quinidine, and the other difference may be the difference in the amount of energy required to succeed in DC recovery. Due to the lack of data on the effect of flecainide on defibrillation threshold in patients with atrial fibrillation, we compared the DC required for intravenous flecainide with or without atrial fibrillation